This is a working overview of reverse-phase HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-09 and is reviewed periodically as new material appears.
Aseptic technique matters when the solution will contact cells or biological reagents. Working in a clean environment, using sterile liquids and containers, and minimizing open-vial time reduce the chance of microbial contamination. Filtration through a sterile filter can remove particles and microorganisms, but some filters adsorb peptides and some peptides are retained by certain membrane materials. Compatibility between the peptide, solvent, and filter should be checked when recovery is critical.
Quality verification after reconstitution may include visual inspection, pH measurement, and chromatographic analysis. Reverse-phase high-performance liquid chromatography can reveal degradation peaks, while mass spectrometry can confirm molecular identity. Concentration may be estimated from the weighed peptide mass or determined by amino acid analysis, UV absorbance, or quantitative chromatography. Documentation of solvent, volume, date, and storage conditions supports traceability and reproducibility. Records also help identify when a solution was prepared and whether it has exceeded an established in-house shelf life.
After a dried peptide is dissolved, the resulting solution is treated as a distinct material with its own stability profile. Temperature, pH, ionic strength, and peptide concentration all influence how long the solution remains suitable for its intended laboratory use. Some sequences are prone to oxidation, deamidation, or aggregation. Because these processes vary widely, no single storage condition applies to every peptide. Buffer composition and light exposure can also shift degradation rates.
Reconstitution concentration is chosen from the mass of peptide and the volume of solvent added. Researchers often prepare a concentrated stock and then divide it into single-use aliquots to reduce freeze-thaw cycling. The actual peptide content may differ from label mass because of counterions, water, or impurities. For that reason, quantitative work may require independent measurement such as amino acid analysis or ultraviolet absorbance. Records of solvent, volume, date, and lot help trace later observations.
Lyophilized peptides are supplied as dry powders or porous cakes that remain stable during shipment and short-term storage. Reconstitution is the laboratory step of adding a suitable solvent so the solid dissolves into a liquid stock. The dried state limits hydrolysis and microbial growth, but it does not remove all residual water or salts. Sequence, counterion, and manufacturing method influence how quickly and completely a peptide enters solution. Researchers treat reconstitution as a practical starting point for later dilution, analysis, or assay work.
| Property | Value | Notes |
|---|---|---|
| Appearance after dissolution | Clear to slightly opalescent solution | Cloudiness or particles may indicate incomplete dissolution, aggregation, or contamination. |
| pH range for stability | Peptide-dependent | Many peptides are most stable near neutral pH, but some require acidic or slightly basic conditions. |
| Common preservative | None for many research uses | Antimicrobial preservatives can alter assays or react with peptides; use depends on application. |
| Typical container material | Borosilicate glass or low-binding plastic | Some peptides adsorb to plastic surfaces; siliconized or low-binding tubes can reduce loss. |
| Common quality check | RP-HPLC, LC-MS, UV absorbance | Identity, purity, and concentration are separate attributes; no single method measures all three. |
The choice of liquid depends on peptide sequence, counterion content, and intended analysis. Water is sufficient for many hydrophilic peptides, while hydrophobic sequences may need a small amount of organic solvent or a buffer. pH can affect charge, solubility, and stability, so the target value is usually selected for the specific peptide. Exact laboratory protocols vary by supplier and application, and no single solvent reliably works for every different peptide.
Reconstitution involves considerably more than simply adding liquid. The solid must wet completely, and gentle mixing should avoid foaming, which can denature some peptides. Insoluble particles may indicate incomplete dissolution, aggregation, or insoluble excipients. The resulting concentration is calculated from the weighed peptide mass and the final volume, not from the volume of liquid added alone. Because peptides can adsorb to surfaces, container material and transfer steps can influence recovery, especially at low concentrations.
After reconstitution, the peptide solution is less stable than the dried powder because water enables hydrolysis, oxidation, and microbial growth. Storage temperature, pH, buffer composition, and container material all affect how long the solution remains usable. Many peptides are kept at 2–8 °C for short-term work, while frozen aliquots at −20 °C or below are used for longer intervals. Repeated freeze-thaw cycles can cause aggregation or precipitation. The choice of storage condition should be based on stability data for the specific peptide.
Quality checks after reconstitution include visual inspection, pH measurement, and analytical methods such as reversed-phase high-performance liquid chromatography. These tests can detect insoluble material, degradation products, and changes in concentration. Mass spectrometry is often used to confirm molecular identity when the peptide sequence is known. Because a clear solution can still contain aggregates or modified peptide, visual clarity alone is not sufficient. Analytical results are compared with a reference standard or the pre-reconstitution certificate of analysis.
Once a peptide is dissolved, its solution is generally less stable than the dry powder. Chemical pathways such as hydrolysis, oxidation, and deamidation can alter the molecule, while physical processes can form aggregates or cause adsorption to container walls. The rate depends on pH, buffer composition, temperature, concentration, and the specific sequence. Aqueous stocks are therefore kept cold and used within a defined period. Stability testing is usually performed for each peptide rather than assumed from a general rule.
Cold storage slows most degradation but does not stop it. Reconstituted solutions are commonly divided into aliquots and held at -20 °C or -80 °C, depending on the peptide. Repeated freeze-thaw cycles can promote aggregation or precipitation, so single-use aliquots are preferred. Some peptides tolerate refrigeration for short intervals, while others require freezing immediately. Light-sensitive residues may need amber or foil-wrapped containers. The optimal condition remains peptide-specific and should be supported by stability data.
Analytical checks can detect changes in a reconstituted stock over time. Reverse-phase high-performance liquid chromatography can show loss of main peak, new impurity peaks, or altered retention. Mass spectrometry confirms molecular identity and can reveal modifications. Visual inspection for particles, color change, or turbidity provides a simple first check. If a solution shows signs of degradation or contamination, it is typically discarded rather than re-purified in a routine laboratory.
Reconstitution is the process of dissolving a lyophilized peptide powder in a suitable liquid to produce a solution for laboratory or clinical use. The dry powder is typically a porous cake or fluffy solid formed by freeze-drying an aqueous or mixed-solvent preparation. Adding solvent restores the peptide to a dissolved state, but the result is not necessarily identical to the original pre-lyophilization solution. Factors such as pH, ionic strength, temperature, and the peptide's sequence influence how completely and quickly dissolution occurs. The term is distinct from dilution, which lowers concentration without changing the physical state of an already dissolved material.
Solvent selection depends on the peptide's charge, hydrophobicity, and intended application. Many lyophilized peptides dissolve readily in water, while others require a small amount of a miscible organic solvent, a dilute acid, or a dilute base before aqueous dilution. A buffer may be used when a stable pH range is known, but adding buffer salts can also promote aggregation or precipitation. Dissolution should be observed rather than assumed, because a clear solution does not prove that the peptide is monomeric or fully active. The order of solvent addition and the final volume matter for achieving the intended concentration.
=== Resident === These CAFs arise from fibroblasts within the vicinity of the tumour that have been recruited by cancer derived growth factor. This process is similar to active inflammation with the main difference between these two processes being that, in cancer, the fibroblasts can't be deactivated which has led to tumours being referred to as “wounds that do not heal.” It is believed that most CAFs arise from differentiated resident fibroblast cells. The normal fibroblast cells receive a hormone signal from nearby cancer cells, indicating that it must become activated, and is thus classed as a CAF. It is unclear why normal fibroblasts transition into CAFs but it has been found that by adding transforming growth factor-β to fibroblasts in culture they start to display features of CAFs. TGF-β is known to control the activation of fibroblasts in inflammation.
Natural fermentation predates human history. Since ancient times humans have exploited fermentation, most likely having unintentionally discovered the process. To store excess foods, humans placed the items in a container which were probably later forgotten, and over time yeast and bacteria started to grow. The earliest archaeological evidence of fermentation is the 13,000-year-old residue of beer, with the consistency of gruel, found in a cave near Haifa, Israel. Another early alcoholic drink, made from fruit, rice, and honey, dates from 7000 to 6600 BC in the Neolithic Chinese village of Jiahu. Winemaking dates from circa 6000 BC in Georgia in the Caucasus area. Seven-thousand-year-old jars containing the remains of wine, now on display at the University of Pennsylvania, were excavated in the Zagros Mountains in Iran. There is strong evidence that people were fermenting alcoholic drinks in Babylon (ca. 3000 BC), ancient Egypt (ca. 3150 BC), pre-Hispanic Mexico (ca. 2000 BC), and Sudan (ca. 1500 BC).
== Other epitope-tag combinations == The principle of tandem-affinity purification of multiprotein complexes is not limited to the combination of CBP and Protein A tags used in the original work by Rigaut et al. (1999). For example, the combination of FLAG- and HA-tags has been used since 2000 by the group of Nakatani to purify numerous protein complexes from mammalian cells. Many other tag combinations have been proposed since the TAP principle was published.
Many different amphibians are neotenic, evolved to retain larval traits (such as external gills) as part of an aquatic lifestyle. For example, Ambystoma mexicanum, an extant salamander, is difficult to tell apart from the Permian temnospondyl Branchiosaurus.
== Further reading == Buckley RH (2004). "Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution". Annu Rev Immunol. 22: 625–55. doi:10.1146/annurev.immunol.22.012703.104614. PMID 15032591. Chinen J, Puck JM (2004). "Successes and risks of gene therapy in primary immunodeficiencies". J Allergy Clin Immunol. 113 (4): 595–603, quiz 604. doi:10.1016/j.jaci.2004.01.765. PMID 15100660. Church AC (2002). "X-linked severe combined immunodeficiency". Hosp Med. 63 (11): 676–80. doi:10.12968/hosp.2002.63.11.1914. PMID 12474613. Gennery AR, Cant AJ (2001). "Diagnosis of severe combined immunodeficiency". J Clin Pathol. 54 (3): 191–5. doi:10.1136/jcp.54.3.191. PMC 1731376. PMID 11253129.
Sources: en.wikipedia.org
Ondarza RN, Abney R, Lopez-Colome AM (1969). "Characterization of a NADPH-dependent coenzyme A-SS-glutathione reductase from yeast". Biochim. Biophys. Acta. 191 (2): 239–48. doi:10.1016/0005-2744(69)90243-5. PMID 4390951. Ondarza RN, Escamilla E, Gutierrez J, De la Chica G (1974). "CoAS-Sglutathione and GSSG reductases from rat liver. Two disulfide oxidoreductase activities in one protein entity". Biochim. Biophys. Acta. 341 (1): 162–71. doi:10.1016/0005-2744(74)90076-x. PMID 4151341. Carlberg I, Mannervik B (1977). "Purification by affinity chromatography of yeast glutathione reductase, the enzyme responsible for the NADPH-dependent reduction of the mixed disulfide of coenzyme A and glutathione". Biochim. Biophys. Acta. 484 (2): 268–74. doi:10.1016/0005-2744(77)90083-3. PMID 334266.
Liberation – How is the active pharmaceutical ingredient disintegrated (for solid oral forms (breaking down into smaller particles), dispersed, or dissolved from the medication? Absorption – How is the active pharmaceutical ingredient absorbed (through the skin, the intestine, the oral mucosa)? Distribution – How does the active pharmaceutical ingredient spread through the organism? Metabolism – Is the active pharmaceutical ingredient converted chemically inside the body, and into which substances. Are these active (as well)? Could they be toxic? Excretion – How is the active pharmaceutical ingredient excreted (through the bile, urine, breath, skin)? Drug metabolism is assessed in pharmacokinetics and is important in drug research and prescribing. Pharmacokinetics is the movement of the drug in the body, it is usually described as 'what the body does to the drug' the physico-chemical properties of a drug will affect the rate and extent of absorption, extent of distribution, metabolism and elimination. The drug needs to have the appropriate molecular weight, polarity etc. in order to be absorbed, the fraction of a drug that reaches the systemic circulation is termed bioavailability, this is simply a ratio of the peak plasma drug levels after oral administration and the drug concentration after an IV administration (first pass effect is avoided and therefore no amount drug is lost). A drug must be lipophilic (lipid soluble) in order to pass through biological membranes because biological membranes are made up of a lipid bilayer (phospholipids etc.).
Specific glycosylation has been shown to occur after the formation of the heptpeptide aglycone. Three separate glycosyl transferases are required for the glycosylation of the teicoplanin aglycone. Tei10* catalyses the addition of GlcNAc to residue 4, followed by deacetylation by Tei2*. The acyl chain (produced by the action of Tei30* and Tei13*) is then added by Tei11*. Tei1 then adds a second GlcNAc to the β-hydroxyl group of residue 6, followed by mannosylation of residue 7 catalysed by Tei3*.
== Function == This gene encodes one of the three alpha chains of type VI collagen, a beaded filament collagen found in most connective tissues. The product of this gene contains several domains similar to von Willebrand factor type A domains. These domains have been shown to bind extracellular matrix proteins, an interaction that explains the importance of this collagen in organizing matrix components. Pathogenic variants in this gene are associated with collagen VI-related dystrophies, a spectrum of disorders that includes Bethlem muscular dystrophy, intermediate collagen VI-related dystrophy, and Ullrich congenital muscular dystrophy. Certain biallelic COL6A2 variants have also been associated with a phenotype referred to as myosclerosis. Three transcript variants have been identified for this gene.
Sources: en.wikipedia.org
== References == Baker J.R. (1958) Principles of biological Microtechnique. London: Methuen. (Also paperback reprint, Franklin Classics Trade Press, USA, 2018. ISBN 978-0353331044.) Horobin R.W. (1982) Histochemistry. Stuttgart: Gustav Fischer. ISBN 3437107003. Horobin R.W. (1988) Understanding Histochemistry. Chichester: Ellis Horwood. ISBN 9780470210604. Kiernan J.A. (2015) Histological and Histochemical Methods, 5th ed. Banbury, UK: Scion. ISBN 9781907904325. Prento P. (2009) Staining of macromolecules: possible mechanisms and examples. Biotech. Histochem. 84: 139-158. Puchtler H. Isler H. (1958) The effect of phosphomolybdic acid on the stainability of connective tissues by various dyes. J. Histochem. Cytochem. 6: 265-270. Reid PE. Iagallo M., Nehr S., Jankunis M., Morrow P. (1993) Mechanism of connective tissue techniques. 1. The effect of dye concentration and staining time on anionic dye procedures. Histochem. J. 25: 821-829.
=== Medium-lived fission products === After several years of cooling, most radioactivity is from the fission products caesium-137 and strontium-90, which are each produced in about 6% of fissions, and have half-lives of about 30 years. Other fission products with similar half-lives have much lower fission product yields, lower decay energy, and several (151Sm, 155Eu, 113mCd) are also quickly destroyed by neutron capture while still in the reactor, so are not responsible for more than a tiny fraction of the radiation production at any time. Therefore, in the period from several years to several hundred years after use, radioactivity of spent fuel can be modeled simply as exponential decay of the 137Cs and 90Sr. These are sometimes known as medium-lived fission products. Krypton-85, the 3rd most active MLFP, is a noble gas which is allowed to escape during current nuclear reprocessing; however, its inertness means that it does not concentrate in the environment, but diffuses to a uniform low concentration in the atmosphere. Spent fuel in the U.S. and some other countries is not likely to be reprocessed until decades after use, and by that time most of the 85Kr will have decayed.
On 3 April, Iranian forces shot down a US Air Force F-15E Strike Eagle fighter jet over the country, with the wreckage falling in the Kohgiluyeh and Boyer-Ahmad province of Iran, the first incident of its kind in more than 20 years. The pilot was rescued that same day, but the WSO remained missing and was rescued alive 48 hours later in a "high-stake" operation involving US special forces supported by 155 aircraft. A US A-10 "Warthog" aircraft was downed and its single crew member ejected near the Strait of Hormuz and was rescued. Iran released a video that, according to Iran, showed the downing of the aircraft using a surface-to-air missile. On the same day, Tehran's Shahid Beheshti University was hit by airstrikes, making the total number of universities hit to more than 30, according to the Iranian Minister of Science.
Sources: en.wikipedia.org
Most reconstituted peptide solutions are kept cold, often at 2–8 °C for short-term use. Longer storage may require freezing at -20 °C or below, depending on the peptide. Repeated freeze-thaw cycles can promote aggregation or degradation.
Freezing concentrates solutes and can expose peptides to ice interfaces, which may unfold or aggregate some sequences. Repeated cycles amplify these stresses. Aliquoting before freezing reduces the number of cycles a single container experiences.
Yes. Some membrane filters bind peptides, especially hydrophobic or positively charged sequences, reducing the amount recovered. Filter material and pore size should be selected with compatibility in mind. Recovery can be checked by comparing pre- and post-filtration analysis when needed.
The solvent depends on peptide sequence and application. Water or aqueous buffer works for many hydrophilic peptides, while hydrophobic peptides may require a water-miscible organic solvent. The chosen solvent must be compatible with the assay or analytical instrument.